About: PRX-03140

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

PRX-03140 is a partial agonist (18% relative to 5-HT) of the 5-HT4 receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease. Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials.

Property Value
dbo:abstract
  • PRX-03140 is a partial agonist (18% relative to 5-HT) of the 5-HT4 receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease. Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials. (en)
dbo:casNumber
  • 869493-21-0
dbo:fdaUniiCode
  • 7QGN8QXG7I
dbo:pubchem
  • 54677674
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 34118574 (xsd:integer)
dbo:wikiPageLength
  • 2990 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1107521629 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 19 (xsd:integer)
dbp:casNumber
  • 869493 (xsd:integer)
dbp:chemspiderid
  • 21377738 (xsd:integer)
dbp:h
  • 27 (xsd:integer)
dbp:iupacName
  • 4 (xsd:integer)
dbp:n
  • 3 (xsd:integer)
dbp:o
  • 3 (xsd:integer)
dbp:pubchem
  • 54677674 (xsd:integer)
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • CCN1C\CCNCCCN3CCCCC3 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • SCHKZZSVELPJKU-UHFFFAOYSA-N (en)
dbp:unii
  • 7 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • PRX-03140 is a partial agonist (18% relative to 5-HT) of the 5-HT4 receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease. Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials. (en)
rdfs:label
  • PRX-03140 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License